

Palivizumab



Included Products: Synagis (palivizumab)

The following are based off the American Academy of Pediatrics 2014 Synagis Guidelines and 2023 AAP and ACIP Recommendations for Nirsevimab:

Created: 11/20/2009

Revised: 11/09/2023

Reviewed: 11/09/2023

Updated: 12/01/2023

All Diagnoses

Initial Criteria	If yes	If no
<p>1. Does the member meet ANY of the following? All referenced ages are as of start of season.</p> <ul style="list-style-type: none"> a. Current age < 12 months at the start of RSV season and gestational age <29 weeks, 0 days, or b. Preterm infants who develop chronic lung disease (CLD) of prematurity defined as birth at gestational age of <32 weeks, 0 days' gestation and a requirement for >21% oxygen for at least 28 days after birth AND one of the following: <ul style="list-style-type: none"> i. Current age <12 months; OR ii. Current age 12-24 months AND continued medical need for supplemental oxygen, chronic corticosteroids, or diuretic therapy during the 6 month period before the start of the RSV season. c. Current age < 12 months with hemodynamically significant congenital heart disease (CHD) and at least one of the following: <ul style="list-style-type: none"> i. acyanotic heart disease who are receiving medication to control CHF and will require cardiac surgical procedures or ii. moderate to severe pulmonary hypertension, or d. Current age ≤ 12 months with congenital abnormalities of the airway or neuromuscular disease that impairs the ability to clear secretions from the upper airways, or e. Age less than 24 months who will be profoundly immunocompromised during RSV season (such as chemotherapy, or post solid organ or stem cell transplant) 	<p>Continue to #2.</p>	<p>Do not approve.</p>

Continued >>

2.	Is the member less than 8 months of age?	Continue to #3.	Continue to #5.
3.	Did the member's birth mother receive the Abrysvo vaccine (RSV vaccine) at least 14 days prior to the member's birth and at 32 through 36 weeks gestational age?	Do not approve. Not medically appropriate	Continue to #4
4.	Is there a reason the member cannot use Beyfortus (nirsevimab), which is covered under the Vaccines for Children program?	Continue to #5.	Do not approve.
5.	Approve Synagis at a dose of 15mg/kg for up to a maximum of 5 total monthly doses until March 31 (projected end of RSV season). Qualifying infants born during RSV season may require fewer doses. If any infant or young child receiving monthly palivizumab prophylaxis experiences a breakthrough RSV hospitalization, monthly prophylaxis should be discontinued.		

REFERENCES

- Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection